Biosyntrx, Inc. Announces New Scientific Advisory Board Members

Steps to the Harvard Library Center of Knowledge. (PRNewsFoto/Biosyntrx, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";COLORADO SPRINGS, Colo., Feb. 18, 2014 /PRNewswire/ -- Biosyntrx, Inc., a nutritional biotechnology and healthy lifestyles education company in the ophthalmic sector is proud to announce the addition of three new scientific advisory board members:

(Photo: http://photos.prnewswire.com/prnh/20140218/SF65884)

Lucy Young, MD, is Associate Professor of Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. She is the director of the Lancaster Course in Ophthalmology and has been on its faculty since 1990. Her publication list includes 95 peer review papers and book chapters. She is on the Best Doctors and U.S. News & World Report Top Doctors lists.

Richard Davis, MD, is a physician, inventor, and successful serial entrepreneur who has authored nearly 400 patents and trademarks worldwide, as well as sold four start-up companies to publicly traded companies. He is currently serving as the Chairman, President, and CEO of OgenX Therapeutics, a privately held mitochondrial medicines company focusing on solutions in Neurodegeneration, Oncology, and Virology in humans and animals.

Vincent de Luise, MD, is Assistant Clinical Professor of Ophthalmology at Yale University School of Medicine and Adjunct Clinical Assistant Professor of Ophthalmology at Weill Cornell Medical College. He serves on the editorial boards of the Cornea Journal and Eye World. As a post-doctoral fellow at Harvard University this past year, he developed a rubric for medical humanities education at both the undergraduate and medical school level.

About Biosyntrx, Inc.: Biosyntrx is a Colorado Springs, Colo.–based Nutritional Biotechnology Company with emphasis on ophthalmic nutrition science, professional crosstalk, and healthy lifestyles education. The primary Biosyntrx Eye Care Professional–recommended products are BioTears, a patented product that addresses the systemic nutrient needs of the dry eye patient, with millions of doses safely used by satisfied repeat customers, Macula Complete, a potent full-spectrum multiple designed for the those concerned about AMD, cataract, diabetic retinopathy, glaucoma, lack of energy, and optimal full-body health, also with millions of doses safely used by satisfied repeat customers. Oculair, a less potent full-body multiple, SightC+ for those who want or need daily or occasional megadoses of mineral-buffered vitamin C, Zeaxanthin-4 for those who want a 4 mg standalone zeaxanthin product, and EpiCor, a clinically proven immune system modulator. ?

For additional information, contact Biosyntrx CEO, Ellen Troyer, at etroyer@biosyntrx.com or office 719-227-7888 or cell 719-660-6676

SOURCE Biosyntrx, Inc.

RELATED LINKS
http://www.biosyntrx.com